When tesamorelin is the more appropriate choice Tesamorelin is typically the preferred agent when: Visceral adipose tissue is the primary treatment target, particularly with associated metabolic comorbidities A clinician is working within a framework that prioritises FDA-approved agents The patient has HIV-associated lipodystrophy, the only approved indication A robust evidence base is required for clinical decision-making For general somatopause-related concerns gradual changes in body composition, sleep quality, and recovery the CJC-1295/ipamorelin combination remains more commonly used, primarily because of its flexible dosing profile and the preserved pulsatile GH release pattern
Consider whether the listed price includes the consultation fee (some charge separately), whether shipping is included, how much medication is included (a one-month supply versus more), whether the price is for the starting dose or the maintenance dose (higher doses cost more), whether follow-up visits are included or charged separately, and whether lab work is included or additional
The Power of Combining Peptides Some wellness practitioners explore combinations of peptides to support more comprehensive recovery
Gradually adjusting the dosage as your doctor prescribes can also help minimize nausea over time
Retatrutide has not received MHRA marketing authorisation and is not licensed for use in the UK
.png)
